Novo Nordisk A/s

This study tests a new medicine, NNC6022-0001, for the first time in humans. It aims to check the drug's safety, how the body processes it, and how it works. Healthy adults aged 18-55 will receive either a single dose of the drug or a placebo. The results will help decide if furt…

This large Phase 3 trial tested whether the diabetes drug semaglutide, taken as a daily pill, can slow cognitive decline in people with early Alzheimer's disease. About 1,840 participants received either semaglutide or a placebo for up to 3 years and 4 months. The study measured …

This study tests a new medicine called NNC0537-1482, designed to potentially treat heart failure. It is the first time this drug is given to humans, so healthy volunteers receive a single injection under the skin to check for safety and how the body processes it. Participants are…

This study tested a new oral medicine called NDec in 96 adults with sickle cell disease. The goal was to see if it safely raises hemoglobin levels and reduces painful crises. Participants took capsules twice weekly for about a year, with some also continuing their usual hydroxyur…

This study tested a new insulin called icodec that is injected just once a week, compared to standard daily insulin shots, in over 1,000 adults with type 2 diabetes who had never used insulin before. The goal was to see if the weekly shot controls blood sugar just as well as dail…

This study tested a new insulin called icodec, taken just once a week, against a standard daily insulin (degludec) in 588 adults with type 2 diabetes who had never used insulin before. Participants received either weekly icodec plus a daily placebo, or daily degludec plus a weekl…

This study tested a new once-a-week injection called IcoSema, which combines insulin and semaglutide, against semaglutide alone in 683 adults with type 2 diabetes. The goal was to see if IcoSema improves blood sugar levels more effectively. Participants received weekly shots for …

This study looked at how safe a new once-weekly insulin (insulin icodec) is during exercise and long periods without food in 30 adults with type 2 diabetes. Participants first took a daily insulin for a week, then switched to the weekly insulin for up to 14 weeks. The goal was to…

This study tested a new once-weekly injection called IcoSema, which combines two diabetes drugs (insulin icodec and semaglutide), against daily insulin glargine in 485 adults with type 2 diabetes whose blood sugar was not well controlled on oral medications. The goal was to see i…

This completed Phase 3 study tested whether adding semaglutide to a new once-weekly insulin (insulin icodec) improves blood sugar control in 148 adults with type 2 diabetes. Participants first received insulin icodec alone for 26 weeks; those with still-high blood sugar then adde…

This study tested a new growth hormone medicine, somapacitan, given once a week, against the standard daily Norditropin in 200 children with growth hormone deficiency. After one year, children receiving the weekly shot grew just as much in height as those on daily shots, with sim…

This completed study followed more than 3,200 Japanese adults with type 2 diabetes who were prescribed Ozempic (semaglutide) by their doctors. Over about 3 years, researchers monitored side effects and checked how well the drug controlled blood sugar and weight. The goal was to s…

This study tested a weekly injection of semaglutide (2.4 mg) to help adults with overweight or obesity lose weight. About 242 people took part, comparing the drug to a placebo over roughly one year. The main goal was to see how much weight they lost and how many lost at least 5% …

This study tested whether adding a weekly semaglutide injection to a lower dose of insulin works as well as a higher dose of insulin alone for controlling blood sugar in people with type 2 diabetes who are overweight. About 573 adults took part for roughly 11 months. The goal was…

This study tested a daily oral semaglutide tablet (50 mg) for weight loss in 667 adults with overweight or obesity. Participants took the pill or a placebo for 68 weeks, along with diet and exercise advice. The main goals were to measure percentage weight loss and how many people…

This study tested an experimental drug, ziltivekimab, in 36 adults with advanced chronic kidney disease (not on dialysis) to see if it can safely reduce inflammation and related heart risks. Participants received either a low dose, a high dose, or a placebo injection every 4 week…

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 300 adults took part, receiving either CagriSema or a dummy shot once a week for around 1½ years. The main goal…

This study tested a new approach for people with type 2 diabetes: a once-weekly insulin injection (insulin icodec) combined with a flash glucose monitor, a small sensor worn on the arm that tracks blood sugar continuously. The goal was to see if this combination helps control blo…

This completed Phase 3 trial tested a high 7.2 mg weekly dose of semaglutide (a drug already used for diabetes and weight loss) in 512 adults with obesity and type 2 diabetes. Participants received either the high dose, a lower dose, or a placebo, along with lifestyle counseling.…

This study followed 28 people with hemophilia B in Japan who were already prescribed Refixia as part of their normal care. Researchers tracked side effects, bleeding episodes, and quality of life to confirm the drug's safety and effectiveness over time. The study did not test a n…

This completed Phase 3 trial tested a high dose (7.2 mg weekly) of semaglutide, a drug already used for weight loss, in 1407 adults with obesity. Participants received the drug or a placebo, plus lifestyle advice. The main goal was to measure weight loss from start to 72 weeks. R…

This study tested a new investigational drug called CagriSema against a currently available medicine, tirzepatide, in over 1,000 adults with type 2 diabetes. The goal was to see which works better at lowering blood sugar and body weight. Participants received weekly injections of…

This study tested a new medicine called NNC0519-0130, given as a weekly injection, to see if it helps people with excess body weight lose weight. About 354 adults with overweight or obesity received different doses of the drug, a placebo, or an existing weight-loss drug for up to…

This study looked at how safe and effective Fiasp, a faster-acting mealtime insulin, is for people with type 1 or type 2 diabetes in everyday life. 42 adults used Fiasp as prescribed by their doctor for about 6 months. Researchers tracked side effects and blood sugar control to s…

This study tested a new medicine (NNC0480-0389) combined with semaglutide, a common diabetes drug, in 500 people with type 2 diabetes. Participants received weekly injections for about 41 weeks. The goal was to see how well the combination lowers blood sugar and to pick the best …

This study tested an experimental drug called etavopivat in 12 children and young adults (ages 12-21) with sickle cell disease. The goal was to see if the drug could improve blood flow and oxygen delivery to the brain and muscles. Participants took the drug and had scans to measu…

This completed Phase 3 trial tested whether oral semaglutide (a drug used for diabetes and weight loss) can slow cognitive decline in 1840 people with early Alzheimer's disease. Participants received either semaglutide or a placebo daily for up to 3 years and 4 months. The study …

This early-phase study tested a new medicine called NNC0363-1063 in 117 healthy volunteers and people with type 1 diabetes. The goal was to check safety, how the body processes the drug, and its effect on blood sugar. The study had three parts, including single and multiple doses…

This study tested a new insulin called icodec that is injected just once a week, compared to the standard daily insulin glargine, in 429 adults with type 2 diabetes. Participants received either the weekly or daily insulin for 6 months. The goal was to see if the weekly shot cont…

This study tested a new fast-acting insulin called NNC0471-0119 in 65 adults with type 2 diabetes who use an insulin pump. Researchers compared how quickly the new insulin enters the bloodstream and lowers blood sugar versus a standard insulin (insulin aspart). The goal is to see…

This completed Phase 1 trial tested a new drug called NNC0519-0130 in 134 overweight or obese adults. The goal was to see if different ways of increasing the dose could reduce side effects. Participants received weekly or twice-weekly injections for about 24 weeks. The study focu…

This study tested a new investigational medicine called CagriSema in 189 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either CagriSema or a placebo injection once a week for about a year. The main goal was…

This early-stage study tested a new medicine, NNC0519-0130, in 20 overweight or obese Chinese men. The goal was to see how the drug moves through the body and if it is safe. Participants received either the drug or a placebo for about 28 weeks. This is not a cure, but aims to hel…

This completed Phase 1 trial tested the safety of a new drug called Inno8 in 95 healthy men. Participants received either Inno8 or a placebo by injection or as tablets. The study measured side effects and how the drug moves through the body. Results will help decide if Inno8 shou…

This study tested whether a new medicine called CagriSema (a combination of two drugs) can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of the two drugs alone, or a pl…

This study tested whether a daily pill called oral semaglutide helps children and teenagers (ages 10 to under 18) with type 2 diabetes control their blood sugar better than a placebo. All participants also took standard diabetes medicines like metformin or insulin. The trial last…

This study tested whether certain drugs (NNC0194-0499, semaglutide, and cagrilintide) can reduce liver damage and alcohol use in people with alcohol-related liver disease. About 270 adults with a history of heavy drinking took part. Participants received different drug combinatio…

This completed Phase 1 trial tested CagriSema, a new combination of two medicines (cagrilintide and semaglutide), in 158 adults with type 2 diabetes. Participants received either CagriSema, one of the individual drugs, or a placebo, alongside their usual metformin. The study meas…

This study looked at whether semaglutide, a medicine used for diabetes and weight loss, can reduce inflammation in the brain and body of people with early Alzheimer's disease. Twenty-three participants with mild memory problems or mild dementia received either semaglutide or a pl…

This study tested a daily 25 mg semaglutide pill in 307 adults with overweight or obesity over 64 weeks. Participants taking the drug lost more weight than those on placebo, with many achieving at least 5% body weight reduction. The pill offers a convenient alternative to injecti…

This study tested a new medicine called NNC0487-0111 for weight control in 36 Chinese adults with overweight or obesity. Participants received either the drug or a placebo injection. The main goal was to check safety and how the drug moves through the body. The trial lasted up to…

This study tested an experimental drug called NNC6019-0001 in 105 people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart, causing heart failure. Participants received either the drug or a placebo by infusion every 4 weeks for a…

This study tested whether a smartphone app helps people with type 2 diabetes stick with their weekly Ozempic injections. 304 participants either used the app or received standard care. The study tracked how long they stayed on the medication and if they reached their target dose.

This study tested a new experimental drug called CagriSema (a combination of cagrilintide and semaglutide) against the existing drug tirzepatide for weight loss in 809 adults with obesity. Participants received weekly injections for about a year and a half. The goal was to see if…

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide) in one weekly injection, for weight loss in 1200 adults who are overweight or obese and have type 2 diabetes. Participants received either CagriSema or a placebo for about 1…

This study tested a weekly injection of semaglutide (2.4 mg) in 207 adults with obesity and prediabetes. Participants received either the drug or a placebo for 12 months, plus lifestyle advice. The goal was to see how much weight they lost and whether their blood sugar returned t…

This study tested a once-weekly injection of semaglutide (2.4 mg) to help people with overweight or obesity lose weight. About 375 adults took part, some receiving the drug and others a placebo, along with lifestyle advice. The main goal was to see how much weight they lost over …

This study looked at whether a once-weekly medicine called semaglutide (used for weight loss and diabetes) can lower the risk of heart attacks, strokes, and death in people with overweight or obesity. Researchers analyzed medical records of over 285,000 people in the US. The goal…

This study tested a new medicine called CagriSema (a mix of two drugs) in 331 East Asian adults with obesity or overweight. Participants received a weekly injection for about 1.5 years. The main goal was to see how much weight they lost compared to another drug. The study is comp…

This study tested whether a daily semaglutide tablet helps Chinese adults with overweight or obesity lose weight. About 200 participants took either the drug or a placebo for 44 weeks, along with guidance on diet and exercise. The main goals were to measure the percentage of weig…

This Phase 3 trial tested CagriSema, a once-weekly injection combining two medicines (cagrilintide and semaglutide), in 2734 adults with type 2 diabetes. The goal was to see if the combo lowers blood sugar and body weight better than either drug alone or a placebo. All participan…

This study tested a new once-weekly growth hormone injection (somapacitan) against the standard daily growth hormone shot in 76 children with growth hormone deficiency who had never been treated before. The main goal was to see how well the weekly shot worked for height growth an…

This study tested how well semaglutide (Wegovy) helps people with obesity lose weight compared to four other approved weight loss medications. About 500 employees from three US companies took part. The goal was to see which drug works best for weight loss and improves quality of …

This study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men with moderate to severe hemophilia B. The medicine is injected into a vein to help blood clot and prevent or treat bleeding episodes. The trial lasted about 12-16 months and checked how well the medi…

This study looked at whether a mobile app called 'Dose Check' helps people with type 2 diabetes control their blood sugar when used with the insulin Tresiba. 179 adults in Saudi Arabia used the app alongside their regular insulin for about 6-7 months. Researchers measured changes…

This study tested a new weekly injection called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help Chinese adults with obesity or overweight lose weight. About 300 participants received either CagriSema, semaglutide alone, or a placebo for around one year…

This phase 2 trial tested whether adding an experimental drug (NNC0165-1875) to the weight-loss medication semaglutide helps people with obesity lose more weight. 120 adults with a BMI between 30 and 45 took part. Participants received either the drug combo or semaglutide plus a …

This completed study looked at the safety and effectiveness of the weight-loss drug Saxenda (liraglutide) in 300 obese adults and teenagers in Taiwan. Participants took the drug as part of their normal care for about 26 weeks. The main goal was to track any side effects and see h…

This study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A, a bleeding disorder. The drug helps blood clot and was given as an injection to prevent or stop bleeding episodes. The trial lasted about 7-8 months and measured how many…

This study tested a new medicine, somapacitan, given once a week against the standard daily growth hormone shot (Norditropin®) in 110 Chinese children with growth hormone deficiency. The goal was to see if the weekly shot works as well as the daily one for helping children grow. …

This study followed 50 adults with type 2 diabetes who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers tracked changes in blood sugar (HbA1c) and body weight over about 8-10 months. Participants also filled out a questionnaire about how they took …

This study followed 244 adults with type 2 diabetes in Japan who were already prescribed Xultophy by their doctor. Researchers tracked blood sugar levels and low blood sugar episodes over 26 weeks to see how well the treatment works in everyday life. The goal was to understand re…

This early-stage study tested a new medicine, NNC0519-0130, given as a weekly injection to help people with obesity or type 2 diabetes. The main goals were to check for side effects and measure how the drug moves through the body. 82 participants were randomly assigned to get eit…

This study tested whether a weekly injection of semaglutide (2.4 mg) helps Asian adults with obesity (BMI 25 or higher) lose weight. About 150 participants received either the drug or a placebo for 44 weeks, along with diet and exercise advice. The main goal was to see how much w…

This study looked at whether using a smart insulin pen (NovoPen 6) with two insulins (Tresiba and Fiasp) helps people with type 1 diabetes achieve better blood sugar levels. About 411 adults took part for 9-11 months, using their own continuous glucose monitor and a mobile app to…

This early study tested a new medicine, NNC0519-0130, in 161 people to see if it is safe and how it works in the body. The medicine aims to lower blood sugar and reduce appetite, which could help people with type 2 diabetes and overweight. Participants received either the medicin…

This study tested a new medicine called NNC0519-0130 in 299 adults with type 2 diabetes. The goal was to see if a once-weekly injection can lower blood sugar and body weight. Participants received up to 7 different doses for about 40 weeks. The results will help find the best dos…

This early-stage trial studied how ziltivekimab works in the body of 24 Chinese adults with chronic kidney disease and signs of inflammation. Participants received either the drug or a placebo as three injections over several weeks. The study measured drug levels and safety, with…

This study tested a drug called ziltivekimab in 264 people with advanced chronic kidney disease and high inflammation. Participants received monthly injections of either a placebo or one of three doses of ziltivekimab for six months. The goal was to see if the drug could safely l…

This study looked at how safe and effective Xultophy (a combination of two diabetes drugs) is for adults with type 2 diabetes when used in everyday medical practice in Korea. About 750 people took part, and the study lasted 26 weeks. The goal was to track side effects and measure…

This completed study looked at how well oral semaglutide (Rybelsus) works for Thai adults with type 2 diabetes in everyday medical practice. Researchers reviewed medical records of 209 patients over 6 months to measure changes in blood sugar (HbA1c) and body weight. The goal was …

This study tested a new medicine called NNC0487-0111 in 448 adults with type 2 diabetes. Participants received either a once-weekly injection, a daily pill, or a placebo for about 43 weeks. The goal was to see how well different doses lower blood sugar and body weight.

This study tested a new long-acting factor IX drug (nonacog beta pegol) in 25 children with hemophilia B. The drug is given as a weekly injection to prevent bleeding episodes. The main goal was to check safety and whether the body develops antibodies that block the treatment. Res…

This study tested whether combining two injectable drugs, cagrilintide and semaglutide, works better than either drug alone for lowering blood sugar in people with type 2 diabetes. 92 adults with type 2 diabetes and a BMI of 27 or higher took part. Participants received weekly in…

This study tested a new long-acting clotting factor drug called nonacog beta pegol in 54 young children with hemophilia B who had not been treated before. The drug was given regularly to prevent bleeding episodes and also to treat any bleeds that occurred. The main goal was to se…

This trial tested a long-acting clotting factor called N8-GP in 124 young children (under 6 years old) with severe hemophilia A who had never been treated before. The goal was to see if it safely prevents and treats bleeding episodes. The study found that N8-GP helped control ble…

This study tested a new medicine called Mim8 for people with hemophilia A, a condition where blood doesn't clot properly. Mim8 is given as a shot under the skin to help prevent bleeding episodes. The trial included 275 healthy volunteers and people with hemophilia A, with or with…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (degludec), in 526 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one over 26 weeks. Participant…

This study tested three different doses of semaglutide (2 mg, 8 mg, and 16 mg) in 245 adults with type 2 diabetes and overweight who were already taking metformin. The main goals were to see how well each dose lowered blood sugar and body weight over 40 weeks. Participants receiv…

This study tested whether a new way of making semaglutide works as well as the current version for controlling blood sugar in people with type 2 diabetes. 388 participants received weekly injections for about 8 months. The main goal was to compare changes in HbA1c levels between …

This study tested whether higher doses (25 mg and 50 mg) of once-daily oral semaglutide work better than the standard 14 mg dose in people with type 2 diabetes. Over 1,600 adults took part, gradually increasing their dose over 68 weeks. The main goals were to see changes in blood…

This study looked at whether semaglutide, a type 2 diabetes medicine, can reduce the risk of major heart problems like heart attacks, strokes, or heart-related death. About 9,600 adults with type 2 diabetes and existing heart disease took either semaglutide tablets or a placebo d…

This study tested whether a weekly injection of semaglutide (2.4 mg) helps teenagers with overweight or obesity lose weight. 201 teens aged 12 to 18 took part, receiving either semaglutide or a placebo for about 15 months, along with lifestyle counseling. The main goal was to see…

This study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those whose bodies make antibodies that block standard treatment. Mim8 helps replace the missing clotting factor and is given as a weekly or monthly injection under the skin. The goa…

This study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 helps prevent bleeding episodes by doing the job of the missing clotting factor. The study included 61 adults and teens who received …

This study tested a new medicine called dasiglucagon against the standard glucagon for treating severe low blood sugar in Asian adults and Japanese teens with type 1 diabetes. About 38 participants received both drugs in random order to see if dasiglucagon raises blood sugar just…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in everyday life for adults with type 2 diabetes in Canada. About 194 people took the medication as prescribed by their doctor and filled out questionnaires over 8-10 months. The main goal was to se…

This study tested a new fast-acting insulin (faster aspart) against a standard insulin (NovoRapid) in 331 adults with type 1 or type 2 diabetes. Both were taken with a long-acting insulin (insulin degludec) for 16 weeks. The goal was to see if the new insulin works better at cont…

This study tested a new once-weekly medicine called IcoSema (a mix of two drugs) against daily insulin injections in 679 adults with type 2 diabetes. Participants received either IcoSema once a week or daily insulin plus mealtime insulin for 52 weeks. The goal was to see if the w…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (glargine), in 582 adults with type 2 diabetes. Participants also used mealtime insulin as needed. The goal was to see if the weekly insulin controls blood sugar …

This study compares a new once-weekly insulin (icodec) to a standard daily insulin (degludec) in 582 adults with type 1 diabetes. Participants receive either weekly or daily injections, plus mealtime insulin, for about a year. The goal is to see if the weekly option controls bloo…

This study tested a new once-weekly injection called IcoSema, which combines insulin icodec and semaglutide, against once-weekly insulin icodec alone in over 1,200 people with type 2 diabetes. The goal was to see if the combo improves blood sugar control more effectively. Partici…

This study looked at how quickly a fast-acting insulin (faster aspart) enters the blood in 23 Chinese adults with type 1 or type 2 diabetes. Participants received one injection of faster aspart and one of the standard insulin NovoRapid, in random order. Blood samples were taken o…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (glargine), in nearly 1,000 adults with type 2 diabetes who had never used insulin before. The main goal was to see if the weekly insulin could control blood suga…

This study tested whether a weekly injection of semaglutide (2.4 mg) can improve heart failure symptoms and reduce body weight in 617 people with obesity-related heart failure with preserved ejection fraction and type 2 diabetes. Participants received either semaglutide or a plac…

This study tested a new investigational medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide) in one weekly injection. It was given to 274 adults with type 2 diabetes who were already taking daily insulin, with or without metformin. The goal was to se…

This completed study compared the effectiveness of once-daily oral semaglutide (Rybelsus) to other oral diabetes medications in 1020 adults with type 2 diabetes who were already taking metformin. Participants were randomly assigned to receive either Rybelsus or another diabetes p…

This study tested whether combining a new liver drug (NNC0194-0499) with semaglutide (a diabetes/weight-loss drug) can reduce liver scarring in people with NASH, a serious fatty liver disease. About 700 adults received weekly injections of either the drug combo, a different combo…

This study tested a new drug called NNC0487-0111, given as an injection under the skin, to see if it is safe and how it works in the body. It included 125 adults aged 18-55 who were overweight or obese. The goal was to help manage weight, but ongoing treatment may be needed.

This study tested a new medicine called Mim8, given as a shot under the skin, to prevent bleeding episodes in children aged 1-11 with hemophilia A (with or without inhibitors). The trial involved 70 participants and compared once-weekly and once-monthly dosing over about 54-98 we…

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday medical practice in Israel. Researchers tracked changes in blood sugar and body weight over about 8-10 months. The goal was to see if the pill helps lower blood …

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral version of semaglutide, a drug that helps lower blood sugar and may aid weight loss. Over about 5-6 months, research…

This study tested the safety and tolerability of a once-weekly injection of semaglutide (0.5 or 1.0 mg) in 104 Chilean adults with type 2 diabetes over 24 weeks. Participants received the drug in escalating doses, with regular blood and urine tests to monitor side effects. The ma…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in real life for adults with type 2 diabetes in Sweden. Researchers tracked blood sugar levels and weight changes over 8-10 months in 194 people who were already prescribed the medication by their d…

This study followed 145 adults with type 2 diabetes who took once-daily oral semaglutide (Rybelsus) as part of their normal care. Researchers measured changes in blood sugar (HbA1c) and body weight over 8-10 months. The goal was to see how well the medication works in everyday li…

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday UK clinics. Researchers tracked blood sugar levels and weight changes over 8-10 months in 336 participants. The goal was to see if the pill helps lower blood sug…

This study followed 99 adults with type 2 diabetes in Denmark who were already prescribed once-daily oral semaglutide (Rybelsus). Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months, along with patient questionnaires. The goal was to see how well t…

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in Mexico. Researchers tracked changes in blood sugar and body weight over 8-10 months. The goal was to see if this pill helps lower blood sugar levels in everyday clinical …

This completed study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in real-world clinics across Spain. Researchers tracked changes in blood sugar (HbA1c), body weight, and how satisfied patients were with their treatment over 8-10…

This completed study in Italy looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday medical practice. Researchers tracked changes in blood sugar and body weight over 8-10 months in 458 participants. The goal was to see if this…

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday clinical practice in Saudi Arabia. Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months in 194 participants. The goal was to see i…

This study followed 650 adults with type 2 diabetes in Japan who were already prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked changes in blood sugar levels and body weight over 8-10 months, along with any side effects. The goal was to see how the medi…

This study tested a new medicine called NNC0662-0419 in 100 adults who are overweight or obese. The main goal was to check if the drug is safe and how the body handles it. Participants received either the drug or a placebo as a weekly injection under the skin. This is the first t…

This completed Phase 1 study tested a new fast-acting insulin called NNC0471-0119 in 43 adults with type 1 diabetes who use an insulin pump. The goal was to see how quickly the insulin enters the bloodstream, how long it works, and how safe it is compared to a standard insulin (i…

This study tested whether semaglutide, a diabetes medicine, improves walking ability in people with type 2 diabetes and peripheral artery disease (narrowed leg arteries). About 792 adults received weekly injections of semaglutide or a placebo for 59 weeks. The main goal was to se…

This study tested how easy and convenient the DuraTouch® device is for injecting insulin. 128 people with type 1 or type 2 diabetes used the device for 12 weeks and rated their satisfaction. The goal was to see if the device improves the daily injection experience.

This completed phase 1 trial tested whether CagriSema, a combination of two drugs (cagrilintide and semaglutide), can reduce how much people with overweight or obesity eat, curb their appetite, and slow stomach emptying. 62 participants received either CagriSema or a placebo for …

This completed Phase 1 study tested how CagriSema (a combination of cagrilintide and semaglutide) affects appetite and brain activity in 164 adults with overweight or obesity. Participants received either the drug, a placebo, or no medicine, and researchers measured appetite scor…

This study looked at whether a weekly injection of semaglutide (a medicine also used for weight loss) can improve heart failure symptoms and daily function in people with obesity-related heart failure. 529 adults with a BMI of 30 or higher took part. Participants received either …

This completed Phase 3 trial tested whether a weekly injection of semaglutide (2.4 mg) could help people with obesity and knee osteoarthritis lose weight and reduce knee pain. 407 participants received either semaglutide or a placebo, along with diet and exercise advice, over 68 …

This completed study observed how 329 Iraqi male patients with haemophilia A used turoctocog alfa (a clotting factor) in their daily care. Researchers reviewed medical records to see how the drug was given and how many bleeding episodes occurred. The goal was to describe real-wor…

This study tests a new medicine called Inno8 for hemophilia A. Researchers want to see how eating and drinking before and after taking the pill changes how much medicine gets into the blood. 80 healthy men aged 18-45 will take one dose after fasting, then wait different times bef…

This study looked at how the body processes a single dose of the drug etavopivat in people with mild, moderate, or severe liver disease compared to those with healthy livers. 48 adults took part. The goal was to understand how liver function affects drug levels and safety, which …

This study watched 23 people with hemophilia A who were already using Esperoct as part of their normal care. Researchers tracked side effects and how well the medicine worked over about two years. The goal was to confirm the drug's safety and effectiveness in everyday use, not to…

This study analyzed health records from nearly 195,000 people in Denmark, Sweden, and Norway to see if semaglutide (the drug in Ozempic and Rybelsus) is linked to a higher risk of pancreatic cancer. Researchers compared new users of semaglutide to new users of other diabetes medi…

This study looked at how a new insulin (NNC0363-1063) interacts with a non-glucose carbohydrate (a type of sweetener) in 36 adults with type 1 diabetes. Participants received fixed doses of the insulin and different amounts of the carbohydrate in random order over 4 tests. The go…

This completed Phase 1 study in 34 adults with overweight or obesity examined whether CagriSema (a combination of cagrilintide and semaglutide) changes how the body processes atorvastatin (a cholesterol drug) and warfarin (a blood thinner). Participants took single doses of atorv…

This study tested whether health data can be collected remotely from adults with overweight or obesity using a smartphone app and connected devices like a watch and scale. 146 participants took part for 24 weeks without any study medicine. The goal was to learn how to run future …

This completed study looked at how well doctors can detect serious and non-serious side effects of the weight-loss drug Saxenda (liraglutide) in 27 Mexican patients with obesity. The main goal was to track cases of pancreatitis and other possible drug reactions. Patients took Sax…

This study tested a new insulin called insulin icodec in 18 children and teenagers (ages 10 to 17) with type 2 diabetes. Each participant received a single injection based on their body weight, and researchers measured how the insulin moved through their blood over time. The goal…

This study looked at how common weight-related health problems are in people of different weights in India, Pakistan, Philippines, and Vietnam. Researchers tracked 1,170 adults for about 2 years without giving any treatment. The goal was to understand which weight groups have mor…

This completed phase 1 study tested how different levels of kidney function affect the processing of a single dose of the experimental drug NNC0519-0130. Thirty-six adults with type 2 diabetes and varying kidney function (normal to severely impaired) received one injection. Resea…

This early-stage study tested a new oral medicine, NNC0705-0001, in 116 healthy adults to see if it is safe and how the body handles it. The drug is being developed to treat chronic inflammation, which can lead to heart and metabolic diseases. Participants received either the dru…

This completed phase 1 trial looked at whether a new experimental drug called NNC0519-0130 changes how the body processes a common birth control pill (ethinylestradiol and levonorgestrel) and how fast the stomach empties. Forty-seven healthy postmenopausal women took part. The go…

This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…

This study follows people who were in the SELECT trial to see how their health changes over the next 10 years. No new medicine is given—participants just fill out a health questionnaire every 6 months. The goal is to learn about long-term effects like heart attacks, cancer, weigh…

This study tested a single injection of a new drug (NNC0194-0499) for non-alcoholic fatty liver disease in 33 people with various degrees of liver impairment and healthy volunteers. The goal was to see how the liver processes the drug and whether it is safe. Results will help det…

This study surveyed 608 heart and kidney doctors to understand their awareness and use of a blood test called hsCRP, which measures inflammation. The goal was to learn what doctors think about inflammation's role in treating patients with heart disease, kidney disease, or heart f…

This study looked at how semaglutide, a diabetes medicine, affects the kidneys in people with type 2 diabetes and chronic kidney disease. 106 participants received either semaglutide or a placebo injection once a week for about a year. Researchers used MRI scans, blood and urine …

This study looked at health data from over 550,000 Chinese adults to see how being overweight or obese affects heart disease. Researchers used national survey information to find out how common heart problems are in this group and how they change over time. No treatments were giv…

This completed phase 1 trial studied how etavopivat, a potential new medicine for sickle cell disease and thalassemia, affects the heart's electrical activity. Thirty-three healthy adults received single doses of etavopivat, a placebo, or an approved heart medication (moxifloxaci…

This study gathered information from 1,061 adults in Saudi Arabia about their weight, blood sugar, heart health, and lifestyle. The goal was to understand how common heart disease is in people with obesity. Participants filled out a questionnaire during a routine doctor visit, an…

This early-stage study tested a new experimental drug, NNC0113-6856, in 70 healthy men to see if it is safe and how the body processes it. Participants received either a single oral dose or an injection into the vein. The goal was to gather initial safety data and measure drug le…

This study tested how different versions of the experimental drug ziltivekimab move through the body when given as a single injection under the skin. It compared two different formulas and two injection methods: a manual syringe and a pen-injector. The study involved 267 healthy …

This completed Phase 1 study tested a single dose of the drug etavopivat in 24 healthy Chinese adults. Researchers measured how much of the drug got into the blood and how long it stayed, as well as any side effects. The goal was to gather basic safety and drug-processing informa…

This study tested two different versions (a tablet and a capsule) of an experimental medicine called NDec, which is being developed for sickle cell disease. 44 healthy adults each took a single dose of both forms to see how the body absorbs them. The goal was to compare the two f…

This early-stage trial tested a single injection of the experimental drug NNC0582-0001 in 56 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo and were followed for a year. The study is complete, but it was not d…

This early-stage study tested a single dose of the experimental medicine NNC0662-0419 in 100 adults with overweight or obesity. Participants were Japanese, Chinese, or non-Asian to see how the drug behaves in different ethnic groups. The main goals were to measure drug levels in …

This study tested whether giving two weight-loss drugs, cagrilintide and semaglutide, in one combined injection works as well as giving them separately. Forty adults with overweight or obesity received weekly injections for 22 weeks. The main goal was to see how the drugs' levels…

This study tests how the experimental drug cagrilintide, being developed for weight management, is processed by the body in people with different levels of liver function. It involves 32 participants, including those with liver impairment and healthy volunteers. The goal is to se…

This study surveyed 1,500 Chinese heart and kidney specialists to understand their awareness and perceptions of systemic inflammation in patients with both atherosclerotic cardiovascular disease and chronic kidney disease. The goal was to learn how doctors currently identify and …

This early study tested a new medicine called NNC0650-0013 in 11 healthy men to see if it is safe and how the body processes it. The drug is being developed for type 2 diabetes. Participants received a single injection under the skin or into a vein, and some got a placebo. The st…

This completed study tested a new tablet version of the drug semaglutide in 264 healthy volunteers. The goal was to measure how much of the drug gets into the blood with the new tablet compared to the current version. Participants took different doses over 21 weeks to see which f…

This completed Phase 1 study tested two different versions of the experimental drug NNC0519-0130 in 46 adults with overweight or obesity. The main goal was to measure how much of the drug gets into the blood and compare the two formulations. Participants received both versions by…

This completed Phase 1 trial tested a single oral dose of monlunabant in 73 healthy Japanese and Caucasian men of normal weight. The main goal was to check safety and how the drug moves through the body. Participants received either monlunabant, placebo, or both, and were monitor…

This completed study from Novo Nordisk looked at 756 adults in the Middle East who have heart disease with or without kidney disease. Researchers measured levels of a protein called hsCRP, which indicates inflammation throughout the body. Participants had one clinic visit and con…

This study tested four different tablet versions of the medicine semaglutide in 90 healthy men. The goal was to see how each tablet is absorbed into the body, not to treat any disease. Participants were randomly assigned to receive one of the tablet versions, and the study lasted…

This study examined how often adults with obesity in the Gulf region have related health issues like diabetes, high blood pressure, and heart disease. Researchers also looked at the medical costs and healthcare use tied to these conditions. The goal was to better understand the r…

This study tested whether a new pen injector delivers the drug Mim8 into the blood as well as a standard syringe and cartridge. 205 healthy men received a single injection of Mim8 using either the pen or the syringe. The goal was to see if the pen works just as well, making it ea…

This early-stage study tested a new medicine called NNC0581-0001 in 48 adults, including healthy volunteers and people with fatty liver (hepatic steatosis). The main goal was to check safety and how the drug moves through the body after a single injection under the skin. Particip…

This study looked at how a high-fat meal changes the amount of the drug etavopivat in the blood of 16 healthy adults. Participants took a single dose of etavopivat after eating a high-fat meal and on an empty stomach on separate days. The goal is to understand if food affects how…

This study tested a new tablet version of semaglutide (the drug in Ozempic and Rybelsus) in 121 healthy men. Researchers wanted to see how different amounts of water (50 mL vs 120 mL) and different delays before breakfast (30, 60, or 120 minutes) affect drug levels in the blood. …

This completed Phase 1 study in 37 healthy adults tested whether a new drug called etavopivat affects how the body processes five common medicines: digoxin, rosuvastatin, midazolam, pitavastatin, and metformin. Participants took etavopivat daily for 10 days along with single dose…